Taimei Technology: Advancing trust and flexibility in global clinical trials

IDC recently released “China Clinical Trial Information System Solutions Market Share, 2022: Riding the Trend*.” The report shows the trends of China’s drug R&D and clinical trial business, and analyzes the characteristics and trends of emerging information technology in the clinical trial field.

Specializing in digital clinical research solutions, Taimei Technology has steadily established itself as a trusted partner and leader within the field, a title solidified by its staggering 21.6% market share (0.7% more than in 2021) in clinical trial information system solutions.

Taimei Technology’s number 1 position in the market can be attributed to its commitment to leveraging digital technologies. The organization strives to redefine the approach to clinical research, aiming not only to streamline processes but also to drive a significant shift in the way data is collected, analyzed, and utilized for medical advancements.

Since its establishment in 2013 in Shanghai, Taimei Technology has diligently supported 2,000+ CROs, large pharmaceutical and biotech companies, research sites, and patients. Taimei Technology is dedicated to providing trust, speed, and flexibility to its customers beyond China’s borders. The organization supports customers globally with offices in USA, France, and Singapore, fostering strong relationships built on reliability and efficiency.

Over the past decade, more than 3,500 studies have utilized Taimei Technology’s eCollect (Electronic Data Capture) and eBalance (Randomization and Trial Supply Management) systems. These studies have spanned across diverse regions, from Pakistan to Denmark, Canada to Spain, or France to Australia. The wide geographical reach showcases the company’s adaptability and commitment to supporting the unique requirements of different regions and study environments, proving Taimei Technology solutions are a right fit for any type of customer.

Taimei Technology is ISO 27001 certified and utilizes AWS (Amazon Web Services) and Alibaba Cloud to enable faster trial execution, aligning with leading cloud service providers. In addition to ISO 27001, Taimei Technology holds several ISO certificates for Quality Management, Information Security, and Service Management, among others, and has successfully passed major SOC2 Type2 assessment areas (security, availability, confidentiality, and privacy) audits and is certified as a CDISC & WHO-UMC Supplier.

In conclusion, Taimei Technology aims to extend its ethos of trust, speed, and flexibility beyond China to its global clientele. The company is positioned to contribute significantly to the future of clinical trials. With an unwavering commitment to excellence, global outreach, and the integration of digital technologies, Taimei Technology is poised to play a pivotal role in transforming the approach and execution of global clinical trials.